Sophia Riesemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sophia Riesemann has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Maximilian Sebastian Schaefer
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Massachusetts; Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Duesseldorf, Germany
7 shared publications - Elena Ahrens
Harvard Medical School Boston MA USA
5 shared publications - Béla-Simon Paschold
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Anaesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ulm, Ulm, Germany
4 shared publications - Theresa Tenge
Medical Faculty and University Hospital Düsseldorf, Heinrich‐Heine‐University Düsseldorf
4 shared publications Guanqing Chen
3 shared publicationsHaobo Ma
3 shared publications
Latest Publications
- 20 August 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Past-Year Cannabis Use in Patients Undergoing Anesthesia and Risk of Postoperative Delirium: A Propensity Score Matched Cohort Study
Was not provided for this article.
- 20 August 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Past-Year Cannabis Use in Patients Undergoing Anesthesia and Risk of Postoperative Delirium: A Propensity Score Matched Cohort Study
Was not provided for this article.
- 26 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 273-275
Primary language other than English and the risk of delirium after surgery in an English-speaking hospital: a retrospective cohort study✰
- 26 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 273-275
Primary language other than English and the risk of delirium after surgery in an English-speaking hospital: a retrospective cohort study✰
- Open Access
- 15 April 2026
- Published by Springer Nature in Journal of Clinical Monitoring and Computing
- Vol. 40 (4) , 1-11
Intraoperative respiratory exchange ratio to predict complications after cardiopulmonary bypass surgery: a retrospective cohort study
- 15 April 2026
- Published by Springer Nature in Journal of Clinical Monitoring and Computing
- Vol. 40 (4) , 1-11
Open AccessIntraoperative respiratory exchange ratio to predict complications after cardiopulmonary bypass surgery: a retrospective cohort study
- Open Access
- 9 April 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 94
Intraoperative allogeneic packed red blood cell transfusions and postoperative delirium: a retrospective cohort study in the USA
- 9 April 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 94
Open AccessIntraoperative allogeneic packed red blood cell transfusions and postoperative delirium: a retrospective cohort study in the USA
- 20 February 2026
- Published by Wiley in Anaesthesia
- Vol. 81 (7) , 933-942
Dose‐dependent relationship between intra‐operative dexmedetomidine and delirium after non‐cardiac surgery: a retrospective cohort study*
Summary: Introduction: Dexmedetomidine can attenuate delirium in patients who are critically ill, but evidence with regards to its preventive effect on postoperative delirium remains equivocal. We hypothesised that the risk of delirium after intra‐operative dexmedetomidine administration varies depending on the dose administered and aimed to identify the optimum dose to mitigate delirium. Methods: We included 114,786 adults undergoing general anaesthesia for non‐cardiac, non‐transplant surgery. Primary exposure was intra‐operative dexmedetomidine dose in cumulative μg.kg ‐1 body weight, dichotomised into high vs. low dose based on the cohort median (0.49 μg.kg ‐1 ). Primary outcome was delirium within 7 days, identified from discharge notes, Confusion Assessment Method assessments and diagnostic codes. Results: A total of 4804 (4.2%) patients received dexmedetomidine, with a median (IQR [range]) cumulative dose of 0.49 (0.28–0.84 [0.01–2.50]) μg.kg ‐1 . Postoperative delirium occurred in 3227 (2.8%) patients. Compared with no dexmedetomidine, the risk of delirium was lower in patients receiving low doses (≤ 0.49 μg.kg ‐1 ) of dexmedetomidine (adjusted odds ratio 0.61, 95%CI 0.44–0.85, p = 0.004), but not among those receiving high doses (> 0.49 μg.kg ‐1 ) (adjusted odds ratio 1.06, 95%CI 0.84–1.34, p = 0.62). Fractional polynomial regression analyses suggested that doses between 0.25 μg.kg ‐1 and 0.35 μg.kg ‐1 were associated with the lowest delirium risk. Threshold regression and restricted cubic splines confirmed these findings. Discussion: Low, but not high, dose dexmedetomidine administration was associated with lower risks of delirium, with optimal doses ranging between 0.25 μg.kg ‐1 and 0.35 μg.kg ‐1 .
- 20 February 2026
- Published by Wiley in Anaesthesia
- Vol. 81 (7) , 933-942
Dose‐dependent relationship between intra‐operative dexmedetomidine and delirium after non‐cardiac surgery: a retrospective cohort study*
Summary: Introduction: Dexmedetomidine can attenuate delirium in patients who are critically ill, but evidence with regards to its preventive effect on postoperative delirium remains equivocal. We hypothesised that the risk of delirium after intra‐operative dexmedetomidine administration varies depending on the dose administered and aimed to identify the optimum dose to mitigate delirium. Methods: We included 114,786 adults undergoing general anaesthesia for non‐cardiac, non‐transplant surgery. Primary exposure was intra‐operative dexmedetomidine dose in cumulative μg.kg ‐1 body weight, dichotomised into high vs. low dose based on the cohort median (0.49 μg.kg ‐1 ). Primary outcome was delirium within 7 days, identified from discharge notes, Confusion Assessment Method assessments and diagnostic codes. Results: A total of 4804 (4.2%) patients received dexmedetomidine, with a median (IQR [range]) cumulative dose of 0.49 (0.28–0.84 [0.01–2.50]) μg.kg ‐1 . Postoperative delirium occurred in 3227 (2.8%) patients. Compared with no dexmedetomidine, the risk of delirium was lower in patients receiving low doses (≤ 0.49 μg.kg ‐1 ) of dexmedetomidine (adjusted odds ratio 0.61, 95%CI 0.44–0.85, p = 0.004), but not among those receiving high doses (> 0.49 μg.kg ‐1 ) (adjusted odds ratio 1.06, 95%CI 0.84–1.34, p = 0.62). Fractional polynomial regression analyses suggested that doses between 0.25 μg.kg ‐1 and 0.35 μg.kg ‐1 were associated with the lowest delirium risk. Threshold regression and restricted cubic splines confirmed these findings. Discussion: Low, but not high, dose dexmedetomidine administration was associated with lower risks of delirium, with optimal doses ranging between 0.25 μg.kg ‐1 and 0.35 μg.kg ‐1 .
- Open Access
- 31 January 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 92
Association of intraoperative dexamethasone administration with postoperative delirium and the role of hyperglycaemia: a retrospective cohort study
- 31 January 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 92
Open AccessAssociation of intraoperative dexamethasone administration with postoperative delirium and the role of hyperglycaemia: a retrospective cohort study
- 4 December 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (3) , 597-610
Changes in Intraoperative Rocuronium Dosing after the Introduction of Sugammadex and Association with Postoperative Respiratory Complications: A Retrospective Cohort Study
Background: Neuromuscular blocking agents dose-dependently precipitate residual neuromuscular blockade and postoperative respiratory complications. The introduction of sugammadex allowed for reversal of even deep neuromuscular blockade and might have provoked more liberal use of neuromuscular blocking agents. The authors investigated whether the introduction of sugammadex led to higher intraoperative rocuronium doses and whether this impacted postoperative respiratory complications. Methods: A total of 163,402 adult patient cases who underwent general anesthesia and received exclusively rocuronium at an academic medical center between 2010 and 2024 were included. Interrupted time series analysis adjusted for patient and procedural characteristics was applied to assess changes in cumulative intraoperative rocuronium doses (milligrams per kilogram body weight) after sugammadex introduction in September 2016. Rocuronium-associated risks of postoperative respiratory complications (postextubation desaturation less than 90%, 7-day reintubation or emergency noninvasive ventilation) and effect modification by use of sugammadex and qualitative (twitch count) versus quantitative (train-of-four ratio) neuromuscular monitoring were evaluated. Reported odds ratios represent the dose–response association (per 1 mg/kg rocuronium increase) within the respective subgroup of patient cases. Results: After a stable baseline (−0.01 mg/kg per year between January 2010 and August 2016; 95% CI, −0.05 to 0.03 mg/kg; P = 0.58), rocuronium doses increased by 0.05 mg/kg annually after introduction of sugammadex (95% CI, 0.03 to 0.07 mg/kg; P < 0.001) from (mean ± SD) 0.83 ± 0.49 mg/kg in August 2016 to 1.20 ± 0.65 mg/kg in January 2024. A total of 9,101 of 108,317 patient cases (8.4%) experienced postoperative respiratory complications. Rocuronium was dose-dependently associated with higher postoperative respiratory complication risks, which was most pronounced among patient cases receiving neither sugammadex nor neuromuscular monitoring (adjusted odds ratio [OR adj ], 1.99 per 1 mg/kg; 95% CI, 1.82 to 2.18; P < 0.001). This association was attenuated when sugammadex was administered (n = 42,141; median dose, 200 mg; interquartile range, 200 to 300 mg; OR adj , 1.08 per 1 mg/kg; 95% CI, 1.01 to 1.16; P = 0.023; P for interaction < 0.001) and abolished with quantitative (n = 25,564; OR adj , 10.94 per 1 mg/kg; 95% CI, 0.85 to 1.03; P = 0.19; P for interaction < 0.001) but not qualitative neuromuscular monitoring (n = 49,045; OR adj , 1.10 per 1 mg/kg; 95% CI, 1.02 to 1.18; P = 0.017; P for interaction < 0.001). Conclusions: Sugammadex introduction was followed by a 45.1% increase in rocuronium doses. While sugammadex attenuated the risk of postoperative respiratory complications, it was completely abolished only with quantitative neuromuscular monitoring.
- 4 December 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (3) , 597-610
Changes in Intraoperative Rocuronium Dosing after the Introduction of Sugammadex and Association with Postoperative Respiratory Complications: A Retrospective Cohort Study
Background: Neuromuscular blocking agents dose-dependently precipitate residual neuromuscular blockade and postoperative respiratory complications. The introduction of sugammadex allowed for reversal of even deep neuromuscular blockade and might have provoked more liberal use of neuromuscular blocking agents. The authors investigated whether the introduction of sugammadex led to higher intraoperative rocuronium doses and whether this impacted postoperative respiratory complications. Methods: A total of 163,402 adult patient cases who underwent general anesthesia and received exclusively rocuronium at an academic medical center between 2010 and 2024 were included. Interrupted time series analysis adjusted for patient and procedural characteristics was applied to assess changes in cumulative intraoperative rocuronium doses (milligrams per kilogram body weight) after sugammadex introduction in September 2016. Rocuronium-associated risks of postoperative respiratory complications (postextubation desaturation less than 90%, 7-day reintubation or emergency noninvasive ventilation) and effect modification by use of sugammadex and qualitative (twitch count) versus quantitative (train-of-four ratio) neuromuscular monitoring were evaluated. Reported odds ratios represent the dose–response association (per 1 mg/kg rocuronium increase) within the respective subgroup of patient cases. Results: After a stable baseline (−0.01 mg/kg per year between January 2010 and August 2016; 95% CI, −0.05 to 0.03 mg/kg; P = 0.58), rocuronium doses increased by 0.05 mg/kg annually after introduction of sugammadex (95% CI, 0.03 to 0.07 mg/kg; P < 0.001) from (mean ± SD) 0.83 ± 0.49 mg/kg in August 2016 to 1.20 ± 0.65 mg/kg in January 2024. A total of 9,101 of 108,317 patient cases (8.4%) experienced postoperative respiratory complications. Rocuronium was dose-dependently associated with higher postoperative respiratory complication risks, which was most pronounced among patient cases receiving neither sugammadex nor neuromuscular monitoring (adjusted odds ratio [OR adj ], 1.99 per 1 mg/kg; 95% CI, 1.82 to 2.18; P < 0.001). This association was attenuated when sugammadex was administered (n = 42,141; median dose, 200 mg; interquartile range, 200 to 300 mg; OR adj , 1.08 per 1 mg/kg; 95% CI, 1.01 to 1.16; P = 0.023; P for interaction < 0.001) and abolished with quantitative (n = 25,564; OR adj , 10.94 per 1 mg/kg; 95% CI, 0.85 to 1.03; P = 0.19; P for interaction < 0.001) but not qualitative neuromuscular monitoring (n = 49,045; OR adj , 1.10 per 1 mg/kg; 95% CI, 1.02 to 1.18; P = 0.017; P for interaction < 0.001). Conclusions: Sugammadex introduction was followed by a 45.1% increase in rocuronium doses. While sugammadex attenuated the risk of postoperative respiratory complications, it was completely abolished only with quantitative neuromuscular monitoring.